Tardive dyskinesia in 2 patients treated with ziprasidone.
Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD). Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy, respectively. One of the patients had had earlier exposure to typical antipsychotic drugs, but no other predisposing factors for TD were noted. Therefore, patients on long-term therapy with atypical antipsychotic drugs should be screened periodically for TD.
Ananth
Jambur
J
Department of Psychiatry, University of California Los Angeles,, Torrance, CA 90509, USA. jananth@rei.edu
Burgoyne
Karl S
KS
Niz
David
D
Smith
Michael
M
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003702:Delusions / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000209:etiology*; D005500:Follow-Up Studies; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008134:Long-Term Care; D008297:Male; D009460:Neurologic Examination / Q000187:drug effects; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone